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Introduction {#sec1}
============

Adipose tissue is an important metabolic regulator of energy balance ([@bib14]). In mammals, three types of adipose tissues exist. White adipose tissue (WAT) is essentially composed of white adipocytes containing one single large lipid vesicle. WAT is mainly located in the abdominal and subcutaneous areas of the body and is highly adapted to store excess energy in the form of triacylglycerides. Conversely, beige and brown adipocytes are highly energy-expending ([@bib16]). They are able to dissipate energy in the form of heat via the action of uncoupling protein-1 (Ucp1) ([@bib28]). Brown adipocytes reside in discrete brown adipose tissue (BAT) depots, such as the interscapular area in rodents, whereas beige adipocytes are intermingled with white adipocytes in WAT. Both brown and beige adipocytes have a multilocular morphology and large numbers of mitochondria and express a common set of brown/beige fat-selective genes, including Ucp1 ([@bib17]). In rodents, heat generated by brown or beige adipocytes via Ucp1 is essential to survive the cold season ([@bib5]). In both cell types, the cold response is mainly regulated by the sympathetic nervous system, in particular by the β3-adrenergic signaling pathway ([@bib4]). In addition to its role in thermogenesis and fatty acid oxidation, it has been reported that BAT activated by the β3-adrenergic signaling pathway can improve glucose homeostasis ([@bib23]).

Because recent studies have shown that brown/beige adipocytes exist in quantifiable amounts in humans ([@bib1]), these fat types have been rediscovered as potential therapeutic targets for weight loss. Therefore, understanding brown/beige adipocyte function and finding new ways to modulate their activity has become a major scientific point of interest ([@bib1]). Among other factors ([@bib12], [@bib13], [@bib24], [@bib30]), the epigenetic regulator lysine-specific demethylase 1 (Lsd1) ([@bib3], [@bib20], [@bib21]), a flavin adenine dinucleotide (FAD)-dependent amine oxidase, has been shown to regulate the differentiation and function of white and beige adipocytes ([@bib6], [@bib22]). In WAT, Lsd1 is induced by cold and involved in mediating the effects of β3-adrenergic signaling. Notably, we recently demonstrated that increased expression of Lsd1 in mouse WAT promotes the development of thermogenically active beige adipocytes and suppresses metabolic disorders such as obesity and type 2 diabetes ([@bib6]). Moreover, in mature white adipocytes, elevation of Lsd1 levels is sufficient to activate mitochondria biogenesis, oxidative phosphorylation, and thermogenesis ([@bib6]). In contrast, the role of Lsd1 in BAT has not been investigated in detail. Brown fat cells exhibit a gene expression profile distinct from either beige or white adipocytes ([@bib33]). Because Lsd1 is a key regulator of metabolism in mature white or beige adipocytes, we asked whether Lsd1 might also play a role in controlling brown adipocyte function.

In this study, we show that selective ablation of Lsd1 or inactivation of its catalytic activity in brown adipocytes triggers a profound whitening of BAT. Lsd1 loss and genetic or chemical inhibition elicits a dramatic rise in expression of WAT-selective genes while impairing the expression of BAT-selective genes. Our data demonstrate that Lsd1 acts via a dual mechanism by positively regulating the expression of BAT-selective genes in cooperation with Nrf1 and actively repressing the expression of WAT-selective genes in concert with the CoREST complex. The whitening of BAT observed upon depletion or inhibition of Lsd1 is accompanied by a shift from oxidative to glycolytic metabolism associated with an accumulation of di- and triacylglycerides. This collapse of BAT function accelerates body weight gain but improves glucose tolerance. Taken together, our results demonstrate that Lsd1 is essential to maintain the metabolic function of brown adipose tissue.

Results {#sec2}
=======

Lsd1 Represses the White Fat Program in Brown Adipose Tissue {#sec2.1}
------------------------------------------------------------

To investigate the role of Lsd1 in BAT, we crossed mice harboring conditional *Lsd1* alleles ([@bib37]) with the *Ucp1-Cre* deleter strain ([@bib29]), which resulted in Cre-mediated loss of Lsd1 selectively in brown and beige adipocytes (*Lsd1*^*Ucp1-Cre*^, hereafter named Lsd1^cKO^) ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). At 10 weeks of age, Lsd1^cKO^ mice exhibited a profound morphological whitening of their BAT ([Figure 1](#fig1){ref-type="fig"}A). This whitening was accompanied by an ∼40% increase in tissue mass ([Figure 1](#fig1){ref-type="fig"}B), a switch from multilocular to unilocular morphology, and increased lipid content ([Figures 1](#fig1){ref-type="fig"}D and 1E). In Lsd1^cKO^ mice, the morphology of mitochondria was severely altered with substantially augmented size and less densely packed cristae ([Figure S1](#mmc1){ref-type="supplementary-material"}C). In accordance, the DNA content of mitochondria was decreased by around 60% in Lsd1^cKO^ mice ([Figure S1](#mmc1){ref-type="supplementary-material"}D), indicating degradation and dysfunction of this organelle. These observations suggested that loss of Lsd1 in brown adipocytes shifted BAT toward a white fat-like phenotype.

Accordingly, we expected to see changes in the transcriptional program of brown adipocytes of Lsd1^cKO^ mice that resemble the gene expression profile observed in white adipocytes. We therefore determined the transcriptome of Lsd1-deleted BAT and compared it with the transcriptome of WAT of control mice, which was described previously ([@bib9]; [Figure 1](#fig1){ref-type="fig"}F; [Table S1](#mmc2){ref-type="supplementary-material"}). The vast majority of WAT-selective genes (95%) was upregulated in BAT of Lsd1^cKO^ mice, whereas 67% of BAT-selective genes showed reduced expression ([Figure 1](#fig1){ref-type="fig"}F; [Table S1](#mmc2){ref-type="supplementary-material"}). qRT-PCR analysis confirmed that the white fat transcriptome was enhanced to the detriment of the brown fat program, as illustrated by significantly increased expression of representative WAT-selective genes such as *Bmp4*, *Egfr*, *Pdk3*, *Fads1*, *Apoe*, *Klhl13*, *Rtn1*, *Bmp1*, and *Wls* ([Figure 1](#fig1){ref-type="fig"}G) and decreased expression of representative BAT-selective genes (*Ucp1*, *Slc27a2*, *Cox8b*, *Acadl*, *Cox6a1*, *Acadm*, *Oplah*, *Prdm16*, and *Cox17*) ([Figure 1](#fig1){ref-type="fig"}H) in Lsd1^cKO^ mice. In line with these RNA expression data, western blot analyses showed that BAT of Lsd1^cKO^ mice expressed higher levels of Apoe and reduced levels of Ucp1 protein ([Figure S1](#mmc1){ref-type="supplementary-material"}E). These data suggest that, in BAT, Lsd1 is required to repress the expression of white fat-selective genes while supporting the brown fat-selective gene expression program.

Lsd1 Demethylase Activity Is Required to Maintain the Gene Expression Program of BAT in Mice {#sec2.2}
--------------------------------------------------------------------------------------------

To determine whether Lsd1 demethylase activity is required to maintain the brown fat program, we engineered mice homozygous for a conditional, enzymatically inactive mutant *Lsd1* knockin allele (*Lsd1*^*KI/KI/Ucp1-Cre*^, hereafter named Lsd1^cKI^) ([Figures S1](#mmc1){ref-type="supplementary-material"}F--S1I). In BAT of these mice, the endogenous Lsd1 gene is replaced by an enzymatically inactive Lsd1 mutant allele following *Ucp1-Cre*-mediated recombination. As observed in Lsd1-depleted mice, we found that BAT of Lsd1^cKI^ mice was increased in size and contained a large proportion of unilocular adipocytes ([Figures 1](#fig1){ref-type="fig"}A and 1C--1E). Although Lsd1 mRNA levels remained unchanged ([Figure S1](#mmc1){ref-type="supplementary-material"}H), the expression levels of WAT-selective genes were increased, whereas the levels of BAT-selective genes were decreased ([Figures 1](#fig1){ref-type="fig"}G and 1H; [Figure S1](#mmc1){ref-type="supplementary-material"}I). In conclusion, alterations in BAT morphology and transcription pattern in Lsd1^cKI^ mice resemble those of Lsd1^cKO^ mice, demonstrating that Lsd1 demethylase activity contributes to the phenotype observed in genetically modified mice.

Because the expression of Ucp1 is initiated in utero between embryonic day (E) 18.5 and E19.5, Lsd1 ablation by *Ucp1-Cre*-mediated recombination is expected to occur around birth ([@bib11]). To investigate the role of Lsd1 in adult BAT, 10-week-old wild-type mice were treated for 5 days with the Lsd1-specific nanomolar affinity inhibitor QC6688 (Lsd1(i)) or vehicle. BAT of mice treated with Lsd1(i) showed a profoundly pale color and increased size compared with that of vehicle-treated mice ([Figure 2](#fig2){ref-type="fig"}A; [Figure S2](#mmc1){ref-type="supplementary-material"}A). H&E staining of BAT sections revealed that Lsd1(i)-treated adipocytes had larger lipid droplets compared with those of vehicle-treated mice ([Figure 2](#fig2){ref-type="fig"}B). The expression levels of representative WAT-selective genes were increased at both mRNA and protein levels ([Figures 2](#fig2){ref-type="fig"}C and 2E), whereas expression of representative BAT-selective genes was decreased in QC6688-treated mice ([Figures 2](#fig2){ref-type="fig"}D and 2E). These data corroborate our findings in Lsd1^cKI^ mice and suggest that catalytically active Lsd1 is required to maintain the metabolic properties of BAT.

To investigate the cell autonomy of Lsd1(i) in BAT, we treated differentiated primary brown adipocytes (hereafter named brown adipocytes) isolated from the stromal vascular fraction with Lsd1(i) or vehicle for 3 days. As shown by oil red O staining, Lsd1(i)-treated brown adipocytes accumulated more fat than vehicle-treated cells ([Figure 2](#fig2){ref-type="fig"}F) and shifted their transcription pattern to a white adipocyte-like program ([Figures S2](#mmc1){ref-type="supplementary-material"}B--S2D). Together, these data demonstrate that the gene expression program of brown adipocytes is controlled by the catalytic activity of Lsd1 in a cell-autonomous manner.

Lsd1 Has a Dual Role in Controlling Expression of BAT- and WAT-Selective Genes {#sec2.3}
------------------------------------------------------------------------------

Next we determined genome-wide Lsd1 chromatin occupancy in brown adipocytes by chromatin immunoprecipitation using Lsd1 antibody followed by massive parallel sequencing (ChIP-seq). The antibody was validated previously and specifically recognizes Lsd1 ([@bib6]). We found that Lsd1 occupied the promoter of 75% of the BAT-selective genes (103 genes) and 68% of the WAT-selective genes (158 genes) differentially regulated in Lsd1^cKO^ mice ([Figure 2](#fig2){ref-type="fig"}G), suggesting a dual mechanism by which Lsd1 represses the expression of WAT-selective genes while activating that of BAT-selective genes.

Hypergeometric optimization of motif enrichment (HOMER) motif searches revealed that promoter occupancy of Lsd1 significantly correlated with the presence of binding sites for the transcription factors Nrf1 and Rest ([Figure 2](#fig2){ref-type="fig"}H). Thus, we hypothesized that Lsd1 might positively regulate BAT-selective genes in cooperation with Nrf1 while repressing WAT-selective gene expression in concert with the CoREST complex. ChIP with Nrf1 antibody followed by qPCR analysis in brown adipocytes showed that Lsd1 and Nrf1 co-localized at promoters of representative BAT-selective genes such as *Acadm*, *Oplah*, and *Cox6a1* ([Figure 3](#fig3){ref-type="fig"}A). *Ucp1* was not part of the analysis because our genome-wide cistrome analysis by ChIP-seq showed no Lsd1 occupancy. Importantly, Nrf1 was not present at the promoter of WAT-selective genes, as illustrated by [Figure S3](#mmc1){ref-type="supplementary-material"}A. Because Lsd1 is known to activate gene expression by erasing dimethyl groups at lysine 9 of histone 3 (H3K9me2), we hypothesized that inhibition of Lsd1 would modify methylation levels of H3K9 at BAT-selective genes. ChIP-qPCR analysis for H3K9me2 revealed that levels of H3K9me2 were increased upon Lsd1(i) treatment at promoters of BAT-selective genes ([Figure 3](#fig3){ref-type="fig"}B). In parallel, levels of H3K4me2 were reduced in Lsd1(i)-treated cells ([Figure S3](#mmc1){ref-type="supplementary-material"}B), indicating a repressive transcriptional context. To investigate whether Lsd1 and Nrf1 are present in the same protein complex, nuclear extracts from brown adipocytes were subjected to size exclusion chromatography. Western blot analysis showed that Lsd1 and Nrf1 co-fractionate, suggesting the existence of an Nrf1/Lsd1complex ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Furthermore, Lsd1 and Nrf1 co-immunoprecipitated, confirming interaction between these two endogenously expressed proteins in BAT ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Accordingly, small interfering RNA (siRNA)-mediated knockdown of Nrf1 ([Figure S3](#mmc1){ref-type="supplementary-material"}E) significantly decreased transcript levels of BAT-selective genes but did not impair WAT-selective gene expression ([Figure 3](#fig3){ref-type="fig"}C). Together, these data demonstrate that Lsd1 controls the expression of BAT-selective genes in cooperation with Nrf1 by targeting H3K9 methylation levels.

Next we analyzed whether an Lsd1-associated repressor complex might regulate the WAT-selective gene program in BAT. For this purpose, nuclear protein extracts from BAT were used for immunoprecipitation with three distinct anti-Lsd1 antibodies directed against various Lsd1 domains followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The intersection of the three interactomes uncovered 163 proteins commonly interacting with Lsd1 ([Figure S3](#mmc1){ref-type="supplementary-material"}F) and revealed the repressive CoREST complex as a significantly enriched protein group ([Table S2](#mmc3){ref-type="supplementary-material"}). Interaction between Lsd1 and CoREST has already been well established ([@bib15], [@bib20], [@bib27]). Accordingly, co-immunoprecipitation experiments and size exclusion chromatography demonstrated that, also in BAT, endogenous Lsd1 interacts with members of the CoREST complex ([Figures S3](#mmc1){ref-type="supplementary-material"}G and S3H). To test whether the CoREST complex indeed represses the expression of WAT-selective genes, we knocked down the complex members Rcor1 and Rcor3 in brown adipocytes ([Figure S3](#mmc1){ref-type="supplementary-material"}I). Cells treated with Rcor1 or Rcor3 siRNA upregulated WAT-selective genes ([Figure 3](#fig3){ref-type="fig"}D) without affecting BAT-selective genes, as exemplified by *Oplah* and *Acadl* ([Figure 3](#fig3){ref-type="fig"}D), and accumulated more lipids than cells treated with control siRNA ([Figure S3](#mmc1){ref-type="supplementary-material"}J). In addition, ChIP-qPCR analyses confirmed the colocalization of Rcor1 and Rcor3 with Lsd1 specifically at promoters of WAT-selective genes ([Figure 3](#fig3){ref-type="fig"}E) but not at promoters of BAT-selective genes ([Figure S3](#mmc1){ref-type="supplementary-material"}K). Because Lsd1 is known to repress gene expression by erasing dimethylation of lysine 4 of histone 3 (H3K4me2), we analyzed whether inhibition of Lsd1 is sufficient to alter methylation levels of H3K4 at WAT-selective genes. ChIP-qPCR analysis showed that levels of H3K4me2 were increased upon Lsd1(i) treatment at promoters of WAT-selective genes ([Figure 3](#fig3){ref-type="fig"}F). Concomitantly, levels of H3K9me2 were decreased at these promoters ([Figure S3](#mmc1){ref-type="supplementary-material"}L), indicating an active transcriptional context. Together, our data demonstrate that Lsd1 represses WAT-selective gene expression in cooperation with the CoREST complex in BAT by reciprocal modulation of H3K4 and H3K9 methylation levels.

Loss of Lsd1 Induces Glycolysis while Repressing Oxidative Metabolism in BAT {#sec2.4}
----------------------------------------------------------------------------

Lsd1^cKO^ mice exhibit a profound morphological whitening of BAT associated with large lipid accumulation. To identify further changes in global gene expression in Lsd1^cKO^ mice that might account for the observed whitening of Lsd1-depleted brown fat, we performed a pathway enrichment analysis of the transcriptome data. The analysis ([Figure 4](#fig4){ref-type="fig"}A) uncovered pathways regulating energy production and fatty acid catabolism such as the tricarboxylic acid (TCA) cycle, electron transport chain (ETC), and β-oxidation. The expression of genes representing these pathways was downregulated ([Figure 4](#fig4){ref-type="fig"}B; [Figure S4](#mmc1){ref-type="supplementary-material"}A), suggesting that oxidative metabolism is lowered in BAT of Lsd1^cKO^ mice, confirming our data in WAT ([@bib6]). Interestingly, the second most enriched pathway was "glycolysis and gluconeogenesis," which we did not observe in WAT. In line with these findings, we observed increased expression of glucose transporters and the majority of glycolytic enzymes catalyzing glucose-to-pyruvate conversion in Lsd1^cKO^ mice ([Figure 4](#fig4){ref-type="fig"}B; [Figure S4](#mmc1){ref-type="supplementary-material"}B). We thus hypothesized that Lsd1 deficiency in BAT not only leads to reduction of oxidative functions but also increases glycolytic capacities. To evaluate bioenergetic changes upon inhibition of Lsd1, we employed a Seahorse XF analyzer (Agilent Technologies) to measure the extracellular acidification rate (ECAR) as an index of glycolytic activity (using a glycolysis stress kit) and the oxygen consumption rate (OCR) as an index of respiratory capacity (using the Cell Mito stress test kit) in brown adipocytes treated with Lsd1(i) or vehicle. The rate of glycolysis following glucose administration was higher upon Lsd1(i) treatment compared with vehicle ([Figure 4](#fig4){ref-type="fig"}C; [Figure S4](#mmc1){ref-type="supplementary-material"}C). After addition of oligomycin, an inhibitor of mitochondrial ATP synthesis, the maximum glycolytic capacity of Lsd1(i)-treated cells remained higher than in control cells, demonstrating that not only the rate of glycolysis but also the glycolytic reserve capacity were enhanced in Lsd1-inactivated cells ([Figure 4](#fig4){ref-type="fig"}C; [Figure S4](#mmc1){ref-type="supplementary-material"}C). In parallel, the OCR was lower in Lsd(i)-treated cells compared with vehicle ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E), and, subsequently, the OCR/ECAR ratio was decreased, demonstrating that Lsd1 inhibition shifted mitochondrial metabolism toward the glycolytic pathway in brown adipocytes ([Figure 4](#fig4){ref-type="fig"}D). Furthermore, oxygen consumption resulting from mitochondrial respiration measured in BAT of Lsd1^cKO^ mice was reduced compared with control mice, confirming lower oxidative phosphorylation ([Figure S4](#mmc1){ref-type="supplementary-material"}F). Taken together, our data show that glycolytic activity is enhanced in the absence of Lsd1, whereas oxidative phosphorylation is reduced.

In addition, glucose uptake and activity of key glycolytic enzymes such as hexokinase (Hk), phosphofructokinase (Pfk), enolase (Eno), and lactate dehydrogenase (Ldh) were higher in BAT of Lsd1^cKO^ mice compared with control mice ([Figure 4](#fig4){ref-type="fig"}E), promoting increased glycolytic capacity.

Of note, the expression levels of genes involved in pyruvate metabolism, including the rate-limiting mitochondrial pyruvate transporters (Mpc1 and Mpc2) and enzymes catalyzing the conversion from pyruvate to acetyl-coenzyme A (CoA) (e.g., Dlat and Pdhx), were decreased in Lsd1^cKO^ mice ([Figure 4](#fig4){ref-type="fig"}B; [Figure S4](#mmc1){ref-type="supplementary-material"}G). Our genome-wide analysis also revealed that expression of glutamic-oxaloacetic transaminase 1 (Got1) and 2 (Got2) as well as Slc25a12 and phosphoenolpyruvate carboxykinase 2 (Pck2) was upregulated in Lsd1^cKO^ mice compared with control ([Figure 4](#fig4){ref-type="fig"}B; [Figure S4](#mmc1){ref-type="supplementary-material"}G). Got1 and 2 are responsible for conversion of downstream pyruvate intermediate oxaloacetate into aspartate and phosphoenolpyruvate, respectively ([@bib2]). In particular, Got1 was shown to be essential for aspartate regeneration to restore ETC dysfunction ([@bib2]). ETC dysfunction is associated with a drop in nicotinamide adenine dinucleotide (NAD^+^)/NADH ratio because NAD^+^ cannot be oxidized by complex I. However, despite decreased oxidative phosphorylation (OXPHOS), the NAD^+^/NADH ratio was increased in BAT of Lsd1^cKO^ mice ([Figure S4](#mmc1){ref-type="supplementary-material"}H). This might be, at least in part, mediated by higher Got1 activity ([Figure 4](#fig4){ref-type="fig"}E). An Increased NAD^+^/NADH ratio is also in favor of increased glycolysis ([@bib36]).

Similarly, expression profiling of metabolic genes in Lsd1^cKI^ mice and mice treated with Lsd1(i) revealed that Lsd1 demethylase activity strongly contributes to maintaining proper energy metabolism in BAT ([Figures S4](#mmc1){ref-type="supplementary-material"}B, S4G, and S4I). Taken together, these data show that glycolysis is enhanced in Lsd1-inactivated BAT, whereas oxidative metabolism is lowered.

The analysis of genome-wide Lsd1 chromatin occupancy in BAT by ChIP-seq revealed that glucose transporters and genes involved in glycolysis are direct targets of Lsd1 ([Figure S4](#mmc1){ref-type="supplementary-material"}J). ChIP-qPCR of brown adipocytes showed promoter occupancy of representative genes by Rcor1, Rcor3, and Lsd1 ([Figure 4](#fig4){ref-type="fig"}F). In parallel, the levels of H3K4me2 were enriched, whereas the levels of H3K9me2 were lowered upon Lsd1(i) treatment ([Figure 4](#fig4){ref-type="fig"}G; [Figures S4](#mmc1){ref-type="supplementary-material"}K and S4L). These results demonstrate that Lsd1 is directly repressing glycolytic genes to ensure physiological metabolic processes in brown adipocytes.

Lsd1 Regulates Lipid Accumulation in BAT {#sec2.5}
----------------------------------------

To further investigate our phenotype, we performed metabolomic and lipidomic analyses of BAT of 10-week-old control and Lsd1^cKO^ mice. These analyses revealed an accumulation of intermediates of glycolysis, including glyceraldehyde-3-phosphate and glycerol, in BAT of Lsd1^cKO^ mice ([Figure 5](#fig5){ref-type="fig"}A) accompanied by augmentation of long-chain diacyl- and triacylglycerides (DAGs and TAGs, respectively) ([Figure 5](#fig5){ref-type="fig"}B). In accordance with an increase in long-chain fatty acids, the transcript levels of fatty acid elongases (Elovl1, Elovl4, and Elovl7) and fatty acid desaturases (Fads1 and Fads2) were upregulated in the absence of Lsd1 ([Figures 4](#fig4){ref-type="fig"}B and [5](#fig5){ref-type="fig"}C) or Lsd1 demethylase activity ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). The analysis of genome-wide Lsd1 chromatin occupancy in BAT by ChIP-seq revealed that genes encoding enzymes involved in fatty acid elongation are direct targets of Lsd1 ([Figures S5](#mmc1){ref-type="supplementary-material"}C--S5F).

DAG and TAG are glycerol esters derived from dihydroxyacetone phosphate (DHAP) and fatty acids. Allocation of fatty acids necessary for glyceride synthesis might be due to decreased lipolysis, increased de novo lipogenesis, or increased fatty acid uptake in BAT of Lsd1^cKO^ mice. Increased fatty acid synthase (Fasn) activity ([Figure 5](#fig5){ref-type="fig"}D) and low acetyl-CoA carboxylase phosphorylation ([Figure S5](#mmc1){ref-type="supplementary-material"}G) are in favor of enhanced de novo lipogenesis in Lsd1^cKO^ mice. To assess lipolysis efficiency, we measured lipase activity. The activity of lipases present in brown adipocytes was reduced by 50% in Lsd1^cKO^ mice, suggesting that hydrolysis of lipids into fatty acids is severely impaired ([Figure 5](#fig5){ref-type="fig"}E). In addition, the activity of lipoprotein lipase (Lpl), which hydrolyzes triglycerides in lipoproteins such as those found in chylomicrons and very low-density lipoprotein (VLDL) to facilitate fatty acid uptake from the bloodstream, was increased upon loss of Lsd1 ([Figure 5](#fig5){ref-type="fig"}F). Finally, to test whether fatty acid oxidation was altered, we measured mitochondrial respiration in the presence of palmitoyl-L-carnitine as substrate in saponine-permeabilized BAT. The data revealed that Lsd1-deficient BAT failed to properly use fatty acids ([Figure 5](#fig5){ref-type="fig"}G). Increased fatty acid synthesis and lower lipolysis are in agreement with the observation of an increased NAD^+^/NADH ratio ([Figure S4](#mmc1){ref-type="supplementary-material"}H). Altogether, these findings show that Lsd1 regulates lipid accumulation in BAT.

In summary, our data show that Lsd1 positively regulates the expression of oxidative metabolism-related genes with concomitant repression of the gene program responsible for glycolysis and fatty acid biosynthesis. Accordingly, loss of Lsd1 in brown adipose tissue drives a shift from oxidative to glycolytic metabolism accompanied by aberrant triglyceride accumulation.

Absence of Lsd1 Improves Glucose Uptake Despite Increasing Body Weight {#sec2.6}
----------------------------------------------------------------------

Finally, we examined the consequences of Lsd1 loss in BAT with aging. Lsd1^cKO^ male mice gained significantly more weight (∼40%) than their control littermates between 10 and 30 weeks of age ([Figure 6](#fig6){ref-type="fig"}A). No weight differences were observed in females ([Figure S6](#mmc1){ref-type="supplementary-material"}A). The weight gain of Lsd1^cKO^ mice was not due to increased food intake or decreased mobility ([Figures S6](#mmc1){ref-type="supplementary-material"}B--S6D). Body composition analysis assessed with a whole-body magnetic resonance analyzer (EchoMRI) revealed that 30-week-old Lsd1^cKO^ mice accumulated more fat than their control littermates, resulting in a lower lean/fat mass ratio compared with control mice ([Figure 6](#fig6){ref-type="fig"}B). These data were corroborated by a dramatically increased BAT mass in 30-week-old Lsd1^cKO^ mice as well as in Lsd1^cKI^ mice ([Figures S6](#mmc1){ref-type="supplementary-material"}E and S6F), associated with ∼45% augmentation in fatty acid content of BAT ([Figure 6](#fig6){ref-type="fig"}C). In accordance, histological analyses revealed a robust phenotypic conversion of BAT in Lsd1^cKO^ and Lsd1^cKI^ mice to a WAT-like appearance ([Figure S6](#mmc1){ref-type="supplementary-material"}G). In addition, we noticed robustly reduced Ucp1 protein levels, as shown by immunocytochemistry ([Figure S6](#mmc1){ref-type="supplementary-material"}G). Observed morphological changes in BAT are accompanied by increased levels of intermediates of glycolysis, glycerol, DAG, and TAG ([Figures S6](#mmc1){ref-type="supplementary-material"}H and S6I).

In 30-week-old Lsd1^cKO^ mice, we observed lower energy expenditure, determined by decreased whole-body oxygen consumption (VO~2~) ([Figure 6](#fig6){ref-type="fig"}D; [Figures S6](#mmc1){ref-type="supplementary-material"}J and S6K) and CO~2~ production (VCO~2~) ([Figure 6](#fig6){ref-type="fig"}E; [Figures S6](#mmc1){ref-type="supplementary-material"}L and S6M), resulting in an increased respiratory quotient (RQ, VCO~2~/VO~2~ ratio) ([Figure 6](#fig6){ref-type="fig"}F). This confirmed a shift in fuel consumption from fatty acids to carbohydrates. In addition, calorimetric parameters deduced from these analyses indicated that energy expenditure was decreased in Lsd1^cKO^ mice ([Figure 6](#fig6){ref-type="fig"}G; [Figures S6](#mmc1){ref-type="supplementary-material"}N and S6O). This was confirmed by body temperature measurements ([Figure 6](#fig6){ref-type="fig"}H).

Next we analyzed mice for glucose tolerance and insulin sensitivity. We observed that circulating glucose levels in 10-week-old Lsd1^cKO^ mice were lower compared with control littermates ([Figure 6](#fig6){ref-type="fig"}I). Nevertheless, we did not notice any difference in glucose tolerance of Lsd1^cKO^ mice relative to control mice at this age ([Figure 6](#fig6){ref-type="fig"}J). Importantly, with aging, control mice developed progressive glucose intolerance, contrary to Lsd1^cKO^ mice, which conserved efficient glucose uptake ([Figure 6](#fig6){ref-type="fig"}J). Age-developed glucose intolerance is generally associated with loss of insulin sensitivity and contributes to type 2 diabetes. To unravel whether Lsd1^cKO^ mice are resistant to age-induced type 2 diabetes, we performed an intraperitoneal insulin sensitivity test (IPIST) and determined serum insulin levels. Despite dramatic alterations in glucose metabolism, we did not observe any difference in insulin sensitivity ([Figure S6](#mmc1){ref-type="supplementary-material"}P) or in total insulin levels ([Figure S6](#mmc1){ref-type="supplementary-material"}Q), showing that only glucose but not insulin metabolism is altered in Lsd1^cKO^ mice. In summary, these data show that Lsd1 is required in BAT to maintain a proper energy balance with aging.

Discussion {#sec3}
==========

White and brown adipocytes have distinct transcriptional programs that facilitate long-term lipid storage or thermogenesis, respectively. Understanding these programs is of the highest interest for developing new strategies to counteract obesity. The epigenetic determinants that regulate white versus brown fat-selective gene expression have not yet been completely elucidated. In this study, we show that the histone demethylase Lsd1 plays a key role in the maintenance of brown fat metabolic properties. Lsd1 accomplishes this mission via a dual mechanism by inhibiting the expression of WAT-selective genes and simultaneously promoting the expression of BAT-selective genes. These opposing functions of Lsd1 are orchestrated by the assembly in different protein complexes: a repressive CoREST complex to inhibit the expression of WAT-selective genes and an Nrf1-containing complex to promote the expression of BAT-selective genes ([Figure 7](#fig7){ref-type="fig"}). Our data point out the importance of Lsd1 demethylase activity in controlling BAT metabolism in vivo. Indeed, our engineered mouse model, Lsd1^cKI^ mice, as well as wild-type mice treated with an Lsd1-specific inhibitor, basically recapitulate the phenotype observed in Lsd1^cKO^ mice. Alterations in BAT morphology and transcriptome in Lsd1^cKI^ and Lsd(i)-treated mice resemble that of Lsd1^cKO^ mice and suggest that catalytically active Lsd1 significantly contributes to the maintenance of the BAT gene expression program and function. However, additional scaffolding functions of Lsd1, which might be independent of the enzymatic activity (i.e., the recruitment of proteins and/or the assembly in different protein complexes) might be impaired upon loss of Lsd1 in Lsd1^cKO^ mice. In contrast, in knockin mice, the enzymatically inactive Lsd1 mutant protein might be able to perform, at least in part, these functions, which might explain a less severe phenotype.

Lsd1 exerts its function in brown adipocytes by engaging in different protein complexes. Coordinated action of Lsd1 with members of the CoREST complex, in particular Rcor1 and Rcor3, represses the expression of WAT-selective genes. Although Lsd1 has been shown to interact with CoREST in various tissues ([@bib15], [@bib20], [@bib27], [@bib34]), the physiological function of CoREST in vivo remains unclear. Here we demonstrate for the time that the CoREST complex plays a critical role in the repression of the WAT-selective genes in BAT, thereby strongly contributing to the maintenance of brown fat characteristics. In BAT, Lsd1 specifically associates with Rcor1 and Rcor3 but not Rcor2. Similar to Lsd1, Rcor1 is ubiquitously expressed in somatic cells, whereas the expression of Rcor2 and Rcor3 seems to be more restricted ([@bib34]). This suggests that the Lsd1 corepressor complex might assemble with different Rcor family members to carry out specific functions in different cell types.

Furthermore, Lsd1 interacts with Nrf1 to activate the expression of BAT-selective genes. We have shown previously that, in WAT, Lsd1 acts together with Nrf1 to positively regulate OXPHOS and thermogenesis ([@bib6]). Elevated Lsd1 levels favor beigening of WAT by increasing oxidative metabolism, uncoupling, thermogenesis, and the number and size of mitochondria. Our data provide evidence that the absence of Lsd1 in BAT causes dramatic mitochondrial dysfunction associated with decreased transcript levels of OXPHOS-related genes. It is interesting that Lsd1 in cooperation with Nrf1 shares comparable functions in beige and brown adipocytes. Whether the mechanism of regulation of oxidative metabolism is conserved in all metabolically active tissues remains unclear. To clarify this hypothesis, it would be necessary to analyze the metabolism of skeletal muscle and liver in Lsd1 knockout mice.

Our analyses uncovered that Lsd1 is necessary to regulate metabolism, particularly fatty acid oxidation, de novo lipogenesis, and lipolysis, leading to increased DAG and TAG accumulation and whitening of Lsd1^cKO^ BAT. In addition, Lsd1 depletion/inhibition leads to elevated glucose uptake and increased glycolytic capacities in mice. This may contribute to DAG and TAG accumulation because the glycerol backbone for triglyceride synthesis can be derived from the glycolytic intermediate dihydroxyacetone phosphate. Furthermore, pyruvate is converted into citrate in the TCA cycle and utilized to provide acetyl-CoA to initiate de novo lipogenesis. However, further experiments would be necessary to provide a direct link between these processes. Nevertheless, the role of Lsd1 in lipid metabolism has been confirmed in this study because Lsd1^cKO^ mice show increased activity of fatty acid synthase and decreased activity of lipases. Altogether, alterations in glycolysis and fatty acid oxidation might contribute to aberrant production of DAG and TAG, which leads to increased fat accumulation.

Transcriptional and metabolic changes induced by Lsd1 ablation have secondary effects on body weight gain and glucose tolerance with aging. Indeed, Lsd1^cKO^ mice gained significantly more weight than their control littermates. These findings are of interest, considering that many mouse models possessing defects in adipose tissue function and metabolism, such as loss of mitochondrial uncoupling ([@bib19]) and fatty acid or ceramide metabolism ([@bib7], [@bib18], [@bib26], [@bib29]), do not develop obesity. A hypothesis might be that Lsd1-deficient brown adipocytes secrete signaling molecules that exert a potential inhibitory function on energy expenditure in other metabolic organs such as white adipose tissue, liver, or muscle. Consequently, we carefully inspected our transcriptome analysis for differential expression of endocrine molecules, cytokines, or other signaling molecules. This analysis failed to identify any known candidates that might explain the phenotype in our mice. This, however, does not exclude the possibility that Lsd1 regulates the expression of yet undescribed endocrine molecules in brown adipocytes. Future studies will be required to elucidate this issue.

Previous studies showed that the ablation of the brown fat-determining transcriptional regulator Prdm16 is required to suppress the expression of WAT-selective genes in BAT ([@bib12]) similar to Lsd1. However, the expression of the most typical BAT-selective genes was only slightly reduced upon *Prdm16* ablation, which could explain why Prdm16 knockout mice are not prone to obesity ([@bib12]). In line with this publication, [@bib35] showed that Lsd1 associates with Prdm16 to repress expression of WAT-selective genes. Of note, our ChIP-seq data identified *Prdm16* as a direct Lsd1 target, and *Prdm16* expression was reduced in Lsd1-deleted BAT. However, immunoprecipitation, size exclusion chromatography, and mass spectrometry analyses did not provide any evidence for association of Lsd1 and Prdm16 in BAT, suggesting that Lsd1 acts upstream of Prdm16. [@bib35] also claim that Lsd1 represses the expression of hydroxysteroid 11-β-dehydrogenase isozyme 1 (*Hsd11b1*) independently from Prdm16. Even though *Hsd11b1* is 1.5-fold upregulated in our Lsd1^cKO^ mice, our cistrome analysis did not provide any evidence for binding of Lsd1 to the Hsd11b1 promoter. Even though the phenotypes of our Lsd1^cKO^ mice and the mice engineered by [@bib35] are close, the differences observed in the follow-up cistrome and transcriptome analyses and the interpretation of the molecular mechanism could be explained by the fact that they did not use a brown fat-specific Cre deleter strain.

Recently, [@bib25] proposed that Zfp516 associates with Lsd1 to promote Ucp1 promoter occupancy and gene expression. In clear contrast, our mass spectrometry analysis does not confirm interaction of endogenously expressed Lsd1 and Zfp516 in brown adipocytes. In addition, our ChIP-seq showed that the Ucp1 promoter is not occupied by Lsd1 in brown adipocytes.

Our findings indicate that the use of Lsd1 inhibitors would lead to a shift from oxidative to glycolytic metabolism in BAT, resulting in weight gain but improved glucose tolerance. These findings need to be considered because Lsd1 inhibitors entered clinical trials, for example in the treatment of mixed-lineage leukemia ([@bib8]). In conclusion, our data identify Lsd1 as a key epigenetic regulator of BAT metabolism.

Experimental Procedures {#sec4}
=======================

Mouse Studies {#sec4.1}
-------------

All mice were housed in the pathogen-free barrier facility of the University Medical Center Freiburg in accordance with institutional guidelines approved by the regional board. Mice were maintained in a temperature- and humidity-controlled animal facility with a 12-hr light/dark cycle, free access to water, and a standard rodent chow (Kliba, breeding, 3807). Male mice were analyzed at 10 or 30 weeks of age. Animals were killed by cervical dislocation, and tissues were immediately collected, weighed, frozen in liquid nitrogen, or processed for further analyses. In vivo experiments, including food consumption, serum analysis, glucose tolerance tests, temperature measurements, and energy expenditure, were described previously ([@bib6]). The Lsd1 inhibitor QC6688 was administrated per os at 5 mg/kg in 0.5% methylcellulose (Sigma; product M0512-110G; viscosity, 4,000 centipoise \[cP\]).

Cellular Metabolism {#sec4.2}
-------------------

Cellular metabolic rates were measured using an XF24 analyzer (Seahorse Bioscience). Immediately before the measurement, cells were washed with unbuffered DMEM as described previously ([@bib32]). Plates were placed into the XF24 instrument for measurement of OCR and ECAR with the XFp glycolysis stress kit (103017-100, Seahorse) for ECAR measurements (glucose, 10 mM; oligomycin, 1 μM; and 2 deoxiglucose (2-DG), 50 mM) or the Cell Mito stress kit (103010-100, Seahorse) for OCR measurements (oligomycin, 1 μM; carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP), 0.5 μM; and rotenone/antimycin A, 0.25 μM).

Lipid Quantification {#sec4.3}
--------------------

Total lipids were extracted from 50 mg of BAT using a lipid extraction kit (STA-612, Cell Biolabs) and quantified using a lipid quantification kit (STA-613, Cell Biolabs) according to the manufacturer's recommendations.

Quantification of Mitochondrial and Nuclear DNA {#sec4.4}
-----------------------------------------------

BAT was digested overnight with Proteinase K, and DNA was extracted with phenol-chloroform. Mitochondria and nuclear DNA were amplified by qPCR using *Cox2* and *Fasn* primers ([Table S4](#mmc1){ref-type="supplementary-material"}), respectively.

Metabolomic and Lipidomic Analyses {#sec4.5}
----------------------------------

Tissue samples were grinded with a Retsch MM440 instrument and further extracted as described in [@bib10]. LC-MS measurements were performed using a Waters ACQUITY ultra performance liquid chromatography (UPLC) system coupled to a Thermo Fisher Scientific QExactive mass spectrometer. Details of the analysis are presented in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Data Analysis {#sec4.6}
-------------

Data are represented as mean + SEM. Significance was calculated by(1)two-tailed Student's t test for [Figures 1](#fig1){ref-type="fig"}G and 1H, [2](#fig2){ref-type="fig"}C and 2D, [4](#fig4){ref-type="fig"}D and 4E, [5](#fig5){ref-type="fig"}C--5G, and [6](#fig6){ref-type="fig"}C--6I and [Figures S1](#mmc1){ref-type="supplementary-material"}A, S1D, [S2](#mmc1){ref-type="supplementary-material"}A, S2C, S2D, [S4](#mmc1){ref-type="supplementary-material"}B, S4C, S4E--S4I, [S5](#mmc1){ref-type="supplementary-material"}A, S5B, [S6](#mmc1){ref-type="supplementary-material"}B--S6E, S6J, S6L, S6N, and S6Q;(2)one-way ANOVA for [Figures 3](#fig3){ref-type="fig"}A and 3C--3E and [4](#fig4){ref-type="fig"}F and [Figures S3](#mmc1){ref-type="supplementary-material"}A, S3E, S3K, and [S5](#mmc1){ref-type="supplementary-material"}D;(3)two-way ANOVA for [Figures 3](#fig3){ref-type="fig"}B and 3F, [4](#fig4){ref-type="fig"}G, and [6](#fig6){ref-type="fig"}A, 6B, and 6J and [Figures S3](#mmc1){ref-type="supplementary-material"}B, S3L, [S4](#mmc1){ref-type="supplementary-material"}K, S4L, [S5](#mmc1){ref-type="supplementary-material"}E, S5F, [S6](#mmc1){ref-type="supplementary-material"}A, and S6P;(4)Wilcoxon rank-sum test for [Figures 5](#fig5){ref-type="fig"}A and 5B and [Figures S6](#mmc1){ref-type="supplementary-material"}H and S6I; and(5)analysis of covariance (ANCOVA) for [Figures S6](#mmc1){ref-type="supplementary-material"}K, S6M, and S6O.

Heatmaps were generated by centering and normalizing expression values with Cluster 3.0 and importing them to MeV viewer.
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![Lsd1 Represses the Expression of WAT-Selective Genes in BAT\
(A--E) Macroscopic view (A), mass (B and C), H&E staining (D), and ultrastructure analysis (E) of representative sections of BAT of control (Ctrl), Lsd1^cKO^, and Lsd1^cKI^ mice.\
(B and C) Mean + SEM, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.\
(B) Ctrl, n = 9; Lsd1^cKO^, n = 7.\
(C) Ctrl, n = 7; Lsd1^cKI^, n = 6.\
(F) Heatmap comparing mRNA levels of BAT- and WAT-selective genes in BAT and WAT of control mice (BAT/WAT) and in BAT of Lsd1^cKO^ and control mice (cKO/Ctrl) at 10 weeks of age (Ctrl, n = 4; Lsd1^cKO^, n = 4).\
(G and H) Relative mRNA levels of WAT-selective (G) and BAT-selective (H) genes in BAT of control, Lsd1^cKO^, and Lsd1^cKI^ mice (mean + SEM, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; Ctrl \[black bars\], n = 9; Lsd1^cKO^ \[orange bars\], n = 7; Ctrl \[white bars\], n = 7; Lsd1^cKI^ \[red bars\], n = 6).\
Scale bars, 5 mm (A), 100 μm (D), 10 μm (E). See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}.](gr1){#fig1}

![The Demethylase Activity of Lsd1 Is Required to Maintain BAT Properties\
(A and B) Macroscopic view (A) and H&E staining (B) of representative sections of BAT of mice treated with vehicle or Lsd1(i).\
(C and D) Relative mRNA levels of WAT-selective (C) and BAT-selective (D) genes in BAT of mice treated with vehicle or Lsd1(i) (mean + SEM, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; vehicle, n = 6; Lsd1(i), n = 7).\
(E) Western blot analysis of Lsd1, Ucp1, and Apoe in BAT of mice treated with vehicle or Lsd1(i). β-Tubulin was used as a loading control.\
(F) Oil red O staining of differentiated primary brown adipocytes treated with vehicle or Lsd1(i).\
(G) Pie chart depicting BAT- and WAT-selective genes with Lsd1 peaks at promoters in differentiated primary brown adipocytes.\
(H) HOMER motif analysis of Lsd1 ChIP-seq data unraveled Rest and Nrf1 binding sites among the top-scoring motifs.\
Scale bars, 5 mm (A), 100 μm (B), 50 μm (F). See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Lsd1 Regulates the Brown Fat Program through a Dual Mechanism\
(A and B) ChIP analysis to detect promoter occupancy performed with anti-Lsd1 and anti-Nrf1 antibodies or rabbit immunoglobulin G (IgG) (rbIgG) in wild-type brown adipocytes (A) and anti-H3K9me2 antibody or mouse IgG (mIgG) in brown adipocytes treated with Lsd1(i) or vehicle (B). The precipitated chromatin was quantified by qPCR analysis with primers flanking Lsd1-binding sites in the indicated genes.\
(C and D) Relative mRNA levels of the indicated BAT- or WAT-selective genes in brown adipocytes transfected with unrelated control siRNA (siRNA Ctrl) or siRNA directed against Lsd1 (siRNA Lsd1) or Nrf1 (siRNA Nrf1) (C) and with siRNA Ctrl or siRNA directed against Rcor1 (siRNA Rcor1) or Rcor3 (siRNA Rcor3) (D).\
(E and F) ChIP analysis to detect promoter occupancy performed with anti-Lsd1, anti-Rcor1, and anti-Rcor3 antibodies or rbIgG in brown adipocytes (E) and anti-Lsd1 and anti-H3K4me2 antibody or rbIgG in brown adipocytes treated with Lsd1(i) or vehicle (F). The precipitated chromatin was quantified by qPCR analysis with primers flanking Lsd1-binding sites in the indicated genes\
Data are mean + SEM. (A), (C), (D), and (E): one-way ANOVA. (B) and (F): two-way ANOVA; ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001; n = 3; qPCRs were run in triplicate. See also [Figure S3](#mmc1){ref-type="supplementary-material"} and [Tables S2](#mmc3){ref-type="supplementary-material"}, [S4](#mmc1){ref-type="supplementary-material"}, and [S5](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Lsd1 Represses Glycolysis in BAT\
(A) Enriched pathways obtained from gene ontology (GO) term analysis for genes differentially expressed in BAT of Lsd1^cKO^ and control mice.\
(B) Heatmaps depicting mean centered normalized mRNA expression of selected genes involved in the TCA cycle, fatty acid elongation, glycolysis, pyruvate processing, and gluconeogenesis in BAT of Ctrl and Lsd1^cKO^ mice at 10 weeks of age (Ctrl, n = 4; Lsd1^cKO^, n = 4).\
(C and D) Representative ECAR (C) and OCR divided by ECAR (D) for Lsd1(i)- or vehicle-treated brown adipocytes determined with the Seahorse extracellular flux analyzer (mean + SEM, ^∗∗∗^p \< 0.001, n = 6).\
(E) Determination of glucose uptake, Hk, Pfk, Eno, Ldh, and Got activities in BAT of Ctrl and Lsd1^cKO^ mice at 10 weeks of age (mean + SEM, ^∗^p \< 0.05, ^∗∗∗^p \< 0.001, n = 5).\
(F and G) ChIP analysis to detect promoter occupancy performed with anti-Lsd1, anti-Rcor1, and anti-Rcor3 antibodies or rbIgG in brown adipocytes (F) and anti-Lsd1 and anti-H3K4me2 antibody or rbIgG in brown adipocytes (G) treated with vehicle or Lsd1(i). The precipitated chromatin was quantified by qPCR analysis with primers flanking Lsd1-binding sites in the indicated genes (mean + SEM). (F): one-way ANOVA. (G): two-way ANOVA. ns: p \> 0.05, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001; n = 3; qPCRs were run in triplicate).\
See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Lsd1 Limits Fat Accumulation in BAT\
(A) Metabolomic analysis of BAT of control and Lsd1^cKO^ mice.\
(B) Lipidomic analysis of BAT from 10-week-old control and Lsd1^cKO^ mice.\
(C) Relative mRNA levels of the indicated enzymes involved in fatty acid elongation in BAT of control and Lsd1^cKO^ mice (mean + SEM; ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; Ctrl, n = 9; Lsd1^cKO^, n = 7).\
(D--F) Determination of fatty acid synthase (Fasn), lipase, and Lpl activities in BAT of Ctrl and Lsd1^cKO^ mice at 10 weeks of age (mean + SEM, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, n = 6).\
(G) Mitochondrial respiration of BAT extracts from Ctrl and Lsd1^cKO^ mice assessed with a high-resolution respiratory Oxygraph-2K system using palmitoyl-L-carnitine as substrate (mean + SEM, ^∗∗∗^p \< 0.001, n = 6).\
See also [Figure S5](#mmc1){ref-type="supplementary-material"} and [Tables S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![Lsd1^cKO^ Mice Have Higher Glucose Uptake Despite Increased Body Weight\
(A) Body weight of control and Lsd1^cKO^ mice at the indicated age (mean + SEM; two-way ANOVA with repeated measures; factor interaction, p~genotype/time~ \< 0.0001; ^∗^p \< 0.05, ^∗∗∗^p \< 0.001; n = 7).\
(B and C) Body fat and lean content(B) and fatty acid content (C) of 30-week-old control and Lsd1^cKO^ mice. (B) and (C): mean + SEM, ^∗^p \< 0.05, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. (B): two-way ANOVA, n = 7. (C): n = 5.\
(D--G) VO~2~ (D), VCO~2~ (E), RQ (F), and energy expenditure (G) of 30-week-old control and Lsd1^cKO^ mice (mean + SEM; ^∗^p \< 0.05, ^∗∗^p \< 0.01; Ctrl, n = 8; Lsd1^cKO^, n = 7). VO~2~, VCO~2~, and energy expenditure are normalized to the lean mass.\
(H) Body temperature of 30-week-old control and Lsd1^cKO^ mice (mean + SEM; ^∗∗^p \< 0.01; Ctrl, n = 8; Lsd1^cKO^, n = 7).\
(I) Serum glucose levels of fed Ctrl and Lsd1^cKO^ mice at the indicated ages (mean + SEM; ^∗^p \< 0.05; Ctrl, n = 8; Lsd1^cKO^, n = 7).\
(J) Intraperitoneal glucose tolerance test (IPGTT) for 10-week-old or 30-week-old control and Lsd1^cKO^ mice starved for 6 hr prior to analysis (mean + SEM; two-way ANOVA; Ctrl 10-week-old versus Lsd1^cKO^ 10-week-old, ns p \> 0.05; Ctrl 10-week-old versus Ctrl 30-week-old, ^∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.0001; Lsd1^cKO^ 10-week-old versus Lsd1^cKO^ 30-week-old, \#\#p \< 0.01, \#\#\#\#p \< 0.0001; Ctrl 30-week-old versus Lsd1^cKO^ 30-week-old, ns p \> 0.05, ˆp \< 0.05, ˆˆˆp \< 0.001, ˆˆˆˆp \< 0.0001; Ctrl, n = 8; Lsd1^cKO^, n = 7).\
See also [Figure S6](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}

![Lsd1 Governs the Gene Expression Program and Metabolic Functions of Brown Adipose Tissue\
Lsd1 controls the properties of BAT via a dual mechanism, resulting in inhibition of WAT-selective and promotion of BAT-selective gene expression. This opposing function of Lsd1 is orchestrated via interaction with (A) the activating transcription factor Nrf1 (H3K4me2 marks are depicted in green) and (B) an Lsd1-containing repressive CoREST complex (H3K9me2 marks are depicted in red).](gr7){#fig7}
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